Ann Lab Med.  2014 May;34(3):198-202. 10.3343/alm.2014.34.3.198.

Diagnostic Utility of Multiprobe Fluorescence in situ Hybridization Assay for Detecting Cytogenetic Aberrations in Acute Leukemia

• Kim BR
• Choi JL
• Kim JE
• Woo KS
• Kim KH
• Kim JM
• Kim SH
• Han JY

• KMID: 1791920
• DOI: http://doi.org/10.3343/alm.2014.34.3.198

Abstract

BACKGROUND
Specific cytogenetic aberrations detected by conventional karyotyping or FISH play a major role in the diagnosis, prognosis, and treatment of patients with acute leukemia. The FISH technique enhances the capacity of conventional karyotyping to detect subtle chromosomal aberrations. Multiprobe FISH assay (Cytocell, UK) can hybridize multiple probes to a single slide, thereby increasing the detection rate of cytogenetic aberrations. This study aimed to evaluate multiprobe FISH in detecting cytogenetic abnormalities in acute leukemia.
METHODS
Thirty newly diagnosed acute leukemia patients who attended the hematology clinic at Dong-A University Hospital from October 2008 to October 2012 were enrolled in the study. The multiprobe FISH results were compared with those of G-banding.
RESULTS
Multiprobe FISH detected the chromosomal aberrations identified by G-banding, as well as additional aberrations in 6 of 30 (20.0%) cases, which included ETV6/RUNX1 translocation, p16 deletion, TP53 deletion, and IGH break-apart.
CONCLUSIONS
The multiprobe FISH assay was a more sensitive and reliable technique compared with G-banding. It was also more cost-effective and yielded faster results.

Keyword

Multiprobe FISH; Acute leukemia; Cytogenetic aberration

MeSH Terms

Acute Disease
Adolescent
Adult
Aged
Child
Child, Preschool
*Chromosome Banding
Core Binding Factor Alpha 2 Subunit/genetics
Gene Deletion
Humans
*In Situ Hybridization, Fluorescence
Karyotyping
Leukemia/*diagnosis
Leukemia, Myeloid, Acute/diagnosis
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
Proto-Oncogene Proteins c-ets/genetics
Repressor Proteins/genetics
Translocation, Genetic
Tumor Suppressor Protein p53/genetics
Young Adult
Core Binding Factor Alpha 2 Subunit
Proto-Oncogene Proteins c-ets
Repressor Proteins
Tumor Suppressor Protein p53

Reference

1. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004; 18:115–136. PMID: 15010150.

2. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001; 14:19–47. PMID: 11355922.

3. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100:4325–4336. PMID: 12393746.

4. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010; 184:16–20. PMID: 19857474.

5. Patsouris C, Micael PM, Campbell LJ. A new nonrandom unbalanced t(17;20) in myeloid malignancies. Cancer Genet Cytogenet. 2002; 138:32–37. PMID: 12419582.

6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33:451–458. PMID: 188440.

7. Valencia A, Cervera J, Such E, Ibañez M, Barragán E, Fuster O, et al. A new reliable fluorescence in situ hybridization method for identifying multiple specific cytogenetic abnormalities in acute myeloid leukemia. Leuk Lymphoma. 2010; 51:680–685. PMID: 20233056.

8. Mascarello JT, Hirsch B, Kearney HM, Ketterling RP, Olson SB, Quigley DI, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011; 13:667–675. https://www.acmg.net/StaticContent/SGs/Section_E_2011.pdf. PMID: 21738013.

9. Shaffer LG, Tommerup N, editors. An international system for human cytogenetic nomenclature. Basel: S. Karger;2005.

10. Shaffer LG, Slovak ML, Campbell LJ, editors. An international system for human cytogenetic nomenclature. Basel: S. Karger;2009.

11. Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn. 2007; 9:134–143. PMID: 17384204.

12. Wiktor AE, Van Dyke DL, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med. 2006; 8:16–23. PMID: 16418595.

13. Kim SR, Kim HJ, Kim SH. Clinical utility of fluorescence in situ hybridization profile test in detecting genetic aberrations in acute leukemia. Korean J Lab Med. 2009; 29:371–378. PMID: 19893343.

14. Lee DY, See CJ, Hwang CD, Cho HI, Lee DS. Analysis of discrepancies between G-banding and FISH in hematologic abnormalities. Korean J Clin Pathol. 2001; 21:445–450.

15. Kwon WK, Lee JY, Mun YC, Seong CM, Chung WS, Huh J. Clinical utility of FISH analysis in additional to G-banded karyotype in hematologic malignancies and proposal of a practical approach. Korean J Hematol. 2010; 45:171–176. PMID: 21120205.

16. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003; 21:277–284. PMID: 12619113.

17. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer. 2007; 46:494–499. PMID: 17311250.

18. Sreekantaiah C. FISH panels for hematologic malignancies. Cytogenet Genome Res. 2007; 118:284–296. PMID: 18000382.

19. Olde Nordkamp L, Mellink C, van der Schoot E, van den Berg H. Karyotyping, FISH, and PCR in acute lymphoblastic leukemia: competing or complementary diagnostics? J Pediatr Hematol Oncol. 2009; 31:930–935. PMID: 19875970.

20. Jamil A, Theil KS, Kahwash S, Ruymann FB, Klopfenstein KJ. TEL/AML-1 fusion gene. its frequency and prognostic significance in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2000; 122:73–78. PMID: 11106814.

21. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Löffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996; 87:495–508. PMID: 8555471.

22. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17:2257–2317. PMID: 14671650.

23. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, et al. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004; 199:673–685. PMID: 14993251.